Susquehanna International Group, LLP Xenon Pharmaceuticals Inc. Call Options Transaction History

Susquehanna International Group, LLP

  • $560 Billion
  • Q3 2024

Call Options

12 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$36.12 - $43.96 $97,524 - $118,692
-2,700 Reduced 25.23%
8,000 $314,000
Q2 2024

Aug 15, 2024
BUY
$36.25 - $43.75 $387,875 - $468,125
10,700 New
10,700 $417,000
Q4 2023

Feb 14, 2024
SELL
$28.7 - $46.46 $441,980 - $715,484
-15,400 Reduced 43.02%
20,400 $939,000
Q3 2023

Nov 14, 2023
BUY
$34.16 - $39.73 $119,559 - $139,055
3,500 Added 10.84%
35,800 $1.22 Million
Q2 2023

Aug 11, 2023
BUY
$34.84 - $43.54 $620,152 - $775,012
17,800 Added 122.76%
32,300 $1.24 Million
Q1 2023

May 16, 2023
BUY
$33.46 - $40.35 $247,604 - $298,590
7,400 Added 104.23%
14,500 $518,000
Q4 2022

Feb 14, 2023
SELL
$33.06 - $39.43 $869,478 - $1.04 Million
-26,300 Reduced 78.74%
7,100 $279,000
Q3 2022

Nov 14, 2022
BUY
$30.79 - $39.82 $723,565 - $935,770
23,500 Added 237.37%
33,400 $1.21 Million
Q2 2022

Aug 15, 2022
SELL
$25.44 - $35.16 $83,952 - $116,027
-3,300 Reduced 25.0%
9,900 $301,000
Q1 2022

May 16, 2022
SELL
$25.09 - $33.13 $1.35 Million - $1.78 Million
-53,700 Reduced 80.27%
13,200 $404,000
Q4 2021

Feb 14, 2022
SELL
$15.6 - $35.4 $1.35 Million - $3.06 Million
-86,500 Reduced 56.39%
66,900 $2.09 Million
Q3 2021

Nov 15, 2021
BUY
$14.86 - $19.45 $2.28 Million - $2.98 Million
153,400 New
153,400 $2.34 Million

Others Institutions Holding XENE

# of Institutions
212
Shares Held
70.2M
Call Options Held
88.3K
Put Options Held
28.8K
View Full List

About Xenon Pharmaceuticals Inc.

XENE Quotes by TradingView
  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.42B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email